MARKET

NBP

NBP

NovaBridge Biosciences
NASDAQ
1.370
+0.040
+3.01%
After Hours: 1.420 +0.05 +3.65% 19:30 10/23 EDT
OPEN
1.310
PREV CLOSE
1.330
HIGH
1.379
LOW
1.260
VOLUME
558.75K
TURNOVER
--
52 WEEK HIGH
5.97
52 WEEK LOW
1.255
MARKET CAP
161.27M
P/E (TTM)
-2.0786
1D
5D
1M
3M
1Y
5Y
1D
Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win
NASDAQ · 1d ago
NovaBridge Biosciences Highlights Phase 1 Ragistomig Data at ESMO 2026
TipRanks · 1d ago
NovaBridge Acquires YOL104-2 From YOLO Via Visara; To Continue Drug Development For OSSN
NASDAQ · 3d ago
NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia
Benzinga · 4d ago
Weekly Report: what happened at NBP last week (1012-1016)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NBP) and Prelude Therapeutics (PRLD)
TipRanks · 10/13 16:40
NovaBridge’s Visara Secures Global License for Neurotrophic Keratitis Therapy VIS-102
TipRanks · 10/13 11:28
Wuhan Hiteck enters exclusive license agreement with Visara
TipRanks · 10/13 11:16
More
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its segments include oncology and ophthalmology. The oncology segment focuses on the research and development of precision immuno-oncology agents for the treatment of cancer. The ophthalmology segment focuses on research and development of ophthalmologic indications such as wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME). Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. VIS-101 targets VEGF-A and ANG-2 to provide more potent treatment benefits for patients with wet AMD and DME.

Webull offers NovaBridge Biosciences stock information, including NASDAQ: NBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBP stock methods without spending real money on the virtual paper trading platform.